Skip to Main Content

1,999

Views

3

CrossRef citations to date

0

Altmetric

Report

IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation

John P. DowlingResearch & Development, Immunome Inc, Exton, PA, USAView further author information

,

Pavel A. NikitinResearch & Development, Immunome Inc, Exton, PA, USAView further author information

,

Fang ShenResearch & Development, Immunome Inc, Exton, PA, USAView further author information

,

Halley ShuklaResearch & Development, Immunome Inc, Exton, PA, USAView further author information

,

James P. FinnResearch & Development, Immunome Inc, Exton, PA, USAView further author information

,

Nirja PatelResearch & Development, Immunome Inc, Exton, PA, USAView further author information

,

Cezary SwiderResearch & Development, Immunome Inc, Exton, PA, USAView further author information

,

Jamie L. Bingaman-SteeleResearch & Development, Immunome Inc, Exton, PA, USAView further author information

,

Chris NicolescuResearch & Development, Immunome Inc, Exton, PA, USAView further author information

,

Eden L SikorskiResearch & Development, Immunome Inc, Exton, PA, USAView further author information

,

Evan J. GreenawaltResearch & Development, Immunome Inc, Exton, PA, USAView further author information

,

Michael J. MorinResearch & Development, Immunome Inc, Exton, PA, USAView further author information

,

Matthew K. RobinsonResearch & Development, Immunome Inc, Exton, PA, USAView further author information

,

Karen LundgrenResearch & Development, Immunome Inc, Exton, PA, USAView further author information

&

Benjamin C. HarmanResearch & Development, Immunome Inc, Exton, PA, USACorrespondence[email protected]

https://orcid.org/0000-0002-3100-9636 View further author information